{"name":"ContraFect Corporation","slug":"contrafect","ticker":"CFRX","exchange":"NASDAQ","domain":"contrafect.com","description":"ContraFect Corporation is a biopharmaceutical company focused on the development of lytic enzymes for the treatment of life-threatening infectious diseases. The company's lead product, CF-301, is in Phase 2 clinical trials for the treatment of Staphylococcus aureus bacteremia, including right-sided endocarditis. ContraFect has a strong pipeline of other lytic enzyme-based products in various stages of development. The company is well-positioned to capitalize on the growing market for anti-infective therapies.","hq":"Yonkers, NY","founded":0,"employees":"","ceo":"Roger Pomerantz","sector":"Anti-Infective Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$18M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CF-301","genericName":"CF-301","slug":"cf-301","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"CF-301","genericName":"CF-301","slug":"cf-301","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-23","type":"earnings","headline":"ContraFect Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"ContraFect reported its financial results for the fourth quarter and full year 2022, including a net loss of $13.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2022-06-28","type":"trial","headline":"ContraFect Announces Positive Interim Results from Phase 2 Clinical Trial of CF-301","summary":"ContraFect announced positive interim results from its Phase 2 clinical trial of CF-301 in patients with Staphylococcus aureus bacteremia, including right-sided endocarditis.","drugName":"","sentiment":"positive"},{"date":"2022-03-14","type":"deal","headline":"ContraFect Announces Collaboration with the National Institutes of Health (NIH) to Develop New Therapies for Infectious Diseases","summary":"ContraFect announced a collaboration with the NIH to develop new therapies for infectious diseases using its lytic enzyme technology.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE02WkF5SGpmc1RLOEo4Y1ktSnJ0Sl85eWFzOXBsM3NZaHhwUFQ4X0dqSG8tZ3BxWDV2OE11SzdQZEpxci13bThseGYxd20wT2xxc3Bz?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"CFRX Stock Price, News & Analysis - Stock Titan","headline":"CFRX Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Merck & Co.","Pfizer Inc.","Gilead Sciences Inc."],"therapeuticFocus":["Infectious Diseases"],"financials":null,"yahoo":null}